Sarcoidosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:16 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Sarcoidosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of XTMAB-16 and Prednisolone in Patients with Pulmonary Sarcoidosis with or without Other Body Involvement https://clinicaltrials.eu/trial/study-on-the-effects-of-xtmab-16-and-prednisolone-in-patients-with-pulmonary-sarcoidosis-with-or-without-other-body-involvement/ Fri, 05 Jun 2026 10:50:15 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-xtmab-16-and-prednisolone-in-patients-with-pulmonary-sarcoidosis-with-or-without-other-body-involvement/ This clinical trial is focused on studying pulmonary sarcoidosis, a condition that affects the lungs and can sometimes involve other parts of the body. The study is testing a new treatment called XTMAB-16, which is given as a solution through an intravenous infusion. The purpose of the study is to evaluate the safety and effectiveness of XTMAB-16 in reducing the need for oral corticosteroids, such as prednisolone, which are commonly used to manage symptoms of sarcoidosis.

Participants in the study will receive either XTMAB-16 or a placebo, which looks like the treatment but does not contain the active ingredient. The study is divided into two parts. In the first part, the focus is on determining the safe dosage levels of XTMAB-16. In the second part, the study will assess how well XTMAB-16 works in reducing the use of corticosteroids. Throughout the study, participants will be monitored for any side effects and changes in their condition.

The study aims to find out if XTMAB-16 can help patients with pulmonary sarcoidosis by allowing them to reduce their reliance on corticosteroids, which can have significant side effects when used long-term. The trial will also gather information on how the body processes XTMAB-16 and its impact on various health markers. This research could lead to new treatment options for those living with this condition.

]]> Study on Long-term Safety of XTMAB-16 for Patients with Pulmonary Sarcoidosis with or without Extra-pulmonary Involvement https://clinicaltrials.eu/trial/study-on-long-term-safety-of-xtmab-16-for-patients-with-pulmonary-sarcoidosis-with-or-without-extra-pulmonary-involvement/ Wed, 29 Apr 2026 15:02:54 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-xtmab-16-for-patients-with-pulmonary-sarcoidosis-with-or-without-extra-pulmonary-involvement/ This clinical trial is focused on studying the long-term effects of a treatment called XTMAB-16 for patients with pulmonary sarcoidosis. Pulmonary sarcoidosis is a condition where clusters of inflammatory cells, known as granulomas, form in the lungs, and it can sometimes affect other parts of the body. The treatment being tested, XTMAB-16, is given as a solution through an intravenous infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of this study is to evaluate the long-term safety and effectiveness of XTMAB-16 in managing pulmonary sarcoidosis, whether or not it involves other parts of the body. Participants in the study will receive the treatment over an extended period, and researchers will monitor them to see how well they tolerate the medication and how it affects their condition. The study will also look at various health measures, such as lung function and quality of life, to understand the overall impact of the treatment.

Throughout the study, researchers will keep track of any side effects or adverse events that participants may experience. They will also assess changes in the use of corticosteroids, which are often used to manage sarcoidosis symptoms, and measure certain biological markers in the blood that can indicate inflammation or disease activity. This information will help determine the long-term benefits and risks of using XTMAB-16 for treating pulmonary sarcoidosis.

]]> Study of XTMAB-16 and Prednisolone Sodium Phosphate for Patients with Pulmonary Sarcoidosis https://clinicaltrials.eu/trial/study-of-xtmab-16-and-prednisolone-sodium-phosphate-for-patients-with-pulmonary-sarcoidosis/ Wed, 29 Apr 2026 14:59:42 +0000 https://clinicaltrials.eu/trial/study-of-xtmab-16-and-prednisolone-sodium-phosphate-for-patients-with-pulmonary-sarcoidosis/ This clinical trial is focused on studying a condition known as pulmonary sarcoidosis, which can sometimes affect other parts of the body beyond the lungs. The trial is testing a new treatment called XTMAB-16, which is given as a solution through an intravenous infusion. The study aims to understand how safe and effective this treatment is for people with pulmonary sarcoidosis, especially in reducing the need for oral corticosteroids, which are commonly used to manage the condition.

The trial is divided into two parts. In the first part, participants will receive different doses of XTMAB-16 to determine the safest and most effective dose for further study. The second part will focus on how well the treatment works in reducing the use of corticosteroids, such as Prednesol (a form of prednisolone), which is often used to control inflammation in sarcoidosis. Participants will be monitored for any side effects and changes in their condition throughout the study.

During the trial, some participants may receive a placebo, which looks like the treatment but does not contain the active ingredient. This helps researchers compare the effects of XTMAB-16 with no treatment. The study will also look at various health markers and quality of life measures to assess the overall impact of the treatment. The goal is to find a new way to manage pulmonary sarcoidosis that could potentially reduce the reliance on corticosteroids and improve patients’ quality of life.

]]> Study on Azithromycin and Doxycycline for Reducing Inflammation in Sarcoidosis Patients https://clinicaltrials.eu/trial/study-on-azithromycin-and-doxycycline-for-reducing-inflammation-in-sarcoidosis-patients/ Wed, 29 Apr 2026 14:29:31 +0000 https://clinicaltrials.eu/trial/study-on-azithromycin-and-doxycycline-for-reducing-inflammation-in-sarcoidosis-patients/ This clinical trial is focused on studying a condition called . Sarcoidosis is a disease where small clusters of inflammatory cells, known as granulomas, form in different parts of the body, most commonly the lungs and lymph nodes. The trial will explore the effects of two medications, and , on reducing inflammation in patients with sarcoidosis. These medications are taken orally in the form of film-coated tablets.

The purpose of the study is to investigate whether treatment with azithromycin and doxycycline can decrease the inflammatory activity in patients with sarcoidosis. The study will also look at a specific type of sarcoidosis related to a bacterium called , which is sometimes found in and around the granulomas. The trial aims to see if the combination of these two medications can significantly reduce inflammation in this type of sarcoidosis.

Participants in the study will receive either the combination of azithromycin and doxycycline or a placebo. The study will monitor the effects of the treatment over a period of time to assess any changes in the inflammatory activity associated with sarcoidosis. The trial is designed to provide valuable insights into the potential benefits of these medications for managing sarcoidosis-related inflammation.

]]> Study on Hydroxychloroquine and Prednisone for Patients with Non-Severe Extra-Pulmonary Sarcoidosis https://clinicaltrials.eu/trial/study-on-hydroxychloroquine-and-prednisone-for-patients-with-non-severe-extra-pulmonary-sarcoidosis/ Wed, 29 Apr 2026 14:24:35 +0000 https://clinicaltrials.eu/trial/study-on-hydroxychloroquine-and-prednisone-for-patients-with-non-severe-extra-pulmonary-sarcoidosis/ This clinical trial is focused on studying a condition called extra-pulmonary sarcoidosis, which affects parts of the body other than the lungs. The study is investigating the use of a medication called hydroxychloroquine as a way to reduce the need for another medication, prednisone, which is a type of steroid. Steroids are often used to treat inflammation in the body, but they can have side effects, so finding ways to use less of them can be beneficial.

The purpose of the study is to see if adding hydroxychloroquine to the treatment plan can help patients with non-severe extra-pulmonary sarcoidosis who need systemic treatment, meaning treatment that affects the whole body. Participants in the study will be randomly assigned to receive either hydroxychloroquine or a placebo, in addition to their regular treatment. The study will last for a period of up to 24 months, with regular check-ups to monitor the effects of the treatment and any side effects.

Throughout the study, doctors will assess how well the treatment is working by looking at the improvement in symptoms and the ability to reduce the use of prednisone. They will also monitor for any side effects related to the medications. The goal is to determine if hydroxychloroquine can effectively help manage the condition while minimizing the need for steroids, ultimately improving the quality of life for patients with extra-pulmonary sarcoidosis.

]]> Study on Stopping Infliximab, Methotrexate, and Azathioprine in Patients with Sarcoidosis in Remission https://clinicaltrials.eu/trial/study-on-stopping-infliximab-methotrexate-and-azathioprine-in-patients-with-sarcoidosis-in-remission/ Wed, 29 Apr 2026 14:22:37 +0000 https://clinicaltrials.eu/trial/study-on-stopping-infliximab-methotrexate-and-azathioprine-in-patients-with-sarcoidosis-in-remission/ This clinical trial is focused on studying the condition known as sarcoidosis, which is a disorder affecting the immune system. The study is evaluating the effects of stopping a treatment with a medication called infliximab, which is used to manage this condition. Infliximab is a type of medication known as a TNF-alpha antagonist, which helps reduce inflammation in the body. The purpose of the study is to compare two different strategies for maintaining remission, which means keeping the disease inactive, in patients who have already achieved remission after being treated with infliximab.

Participants in the study will be divided into groups to test these strategies. Some participants will continue with their current treatment, while others will stop taking infliximab. The study will monitor the participants over a period of time to see how many experience a major relapse, which is when the disease becomes active again. This will help researchers understand the best way to manage sarcoidosis after initial treatment with infliximab.

In addition to infliximab, the study also involves other medications such as methotrexate and azathioprine, which are taken in tablet form. Methotrexate is a chemical substance used to treat various immune system disorders, while azathioprine is another medication that helps suppress the immune system to prevent it from attacking the body. The study will last for up to 12 months, and participants will receive either the medication or a placebo during this time. The results will provide valuable information on how to best maintain remission in patients with sarcoidosis.

]]> SARKO https://clinicaltrials.eu/organisation/sarko/ Wed, 29 Apr 2026 13:34:17 +0000 https://clinicaltrials.eu/organisation/sarko/ Polskie Stowarzyszenie Chorych na Sarkoidozę (Polish Sarcoidosis Patients Association), known as “Sarko Stowarzyszenie,” was established in 2010 by patients themselves, driven by the need to create a supportive network for others living with sarcoidosis. The core mission of the association is to connect Polish patients with sarcoidosis and their families, fostering a vital space for the exchange of experiences and knowledge.

]]>